<DOC>
	<DOCNO>NCT02483858</DOCNO>
	<brief_summary>This open-label , multi-center , non-randomized , dose escalation Phase 1 study evaluate safety , tolerability , PK efficacy PQR309 treatment select patient advanced solid tumor .</brief_summary>
	<brief_title>Study Oral PQR309 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This open-label , multi-center , non-randomized , dose escalation Phase 1 study evaluate safety , tolerability , PK efficacy PQR309 treatment select patient advanced solid tumor . In initial phase study , patient treat daily disease progression , unacceptable toxicity , patient ` request withdrawal , investigator judgment death whichever come first . Enrollment initial patient cohort 3 6 patient follow traditional 3 + 3 dose escalation scheme evaluate Dose Levels 1 - 5 continuous q.d dose schedule . Patients treat PQR309 start Dose Level 1 enrol exceptionally 6 patient ( applicable continuous dose schedule ) . Subsequent patient cohort ( ) enrol depend safety tolerability initial cohort . If &lt; 33 % patient treat Dose Level 1 ( 80 mg ) experience Dose Limiting Toxicities ( DLT - see definition ) end first treatment cycle ( 21 day ) , next cohort 3 patient enrol treated Dose Level 2 continuous dose schedule , 2 treatment-related DLTs observe Dose Level 1 , patient accrue Dose Level -1 . If 2 patient experience DLT dose Level 2 ( 120 mg ) , dose 100 mg explore next.The MTD define maximum dose level ≤ 1/6 patient DLTs . After MTD establish continuous dosing schedule , study expand evaluate MTD intermittent dose schedule . Initially 2 additional dosing schedule , intermittent schedule A B , evaluate parallel . Patients assign two schedule alternate manner . Patients treat within dose schedule cohort enrol . No within-patient dose escalation alteration dose schedule allowed.Both schedule A B evaluate intermittent dose 21 day cycle : Intermittent schedule A : Two day daily PQR309 administration follow treatmentfor 5 day . Intermittent schedule B : PQR309 administration Monday Thursday . Same dose escalation procedure apply intermittent schedule evaluation continuous schedule . Based overall evaluation safety tolerability , PK data intermittent dose schedule continuous schedule well PQR309 non-clinical data , evaluation additional dosing schedule may consider investigated agree sponsor study investigator . After MTD establish intermittent dosing schedule , study expand evaluate MTD one select schedule patient : - Solid tumor PI3K/mTOR pathway activation - HPV positive HNSCC patient contain activate PIK3CA mutation Evaluation data cohort allow complete evaluation tolerability , pharmacokinetics , correlative endpoint well preliminary clinical efficacy PQR309 .</detailed_description>
	<criteria>Inclusion Criteria 1 . Patients ≥ 18 year age . 2 . Histologically cytologically confirm diagnosis solid malignancy , standard curative life prolong therapy available . 3 . Have ECOG Performance Status ≤ 1 . Refer Appendix 1 . 4 . Life expectancy ≥ 12 week . 5 . Adequate bone marrow , liver , renal function , define : Platelet count ≥ 100 x 109/L , absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L , Hemoglobin ≥ 9 g/dL . ALT AST ≤ 2.5 upper limit normal ( ULN ) , &lt; 5 x ULN liver metastases present ; serum total bilirubin ≤ ULN 1.5 x ULN liver metastases present total 3 x ULN direct bilirubin ≤ ULN patient well document Gilbert Syndrome . Serum Creatinine &lt; 1.5 x ULN ( upper limit normal ) estimate creatinine clearance ≥ 60 mL/min , calculate use method standard institution ( Appendix 2 ) . 6 . Glycated hemoglobin ( HgbA1c ) ≤ 7 % ; Fasting Plasma Glucose ( FPG ) ≤ 7.0 mmol/L ( 125 mg/dL ) . 7 . Women childbearing potential must negative pregnancy test ( urine serum ) perform within 7 day prior start study drug . 8 . Able willing swallow retain oral medication . 9 . Subject legal representative must understand investigational nature study sign Independent Ethics Committee/Institutional Review Board approve write informed consent form prior receive study related procedure . Expansion part : 10 . Patients must know PI3K/mTOR pathway gene aberration ( molecular profiling study ) . 11 . Patients must HPV positive HNSCC contain activate PIK3CA mutation . Exclusion Criteria 1 . Concurrent previous anticancer chemotherapy , immunotherapy investigational agent &lt; 3 week , palliative radiation &lt; 2 week prior first day study treatment . Patients receive gamma knife radiosurgery brain metastasis whole brain radiation eligible gamma knife radiosurgery perform &gt; 2 week treatment start whole brain radiation perform &gt; 4 week treatment start , clinically stable . 2 . Hormonal anticancer therapy except LHRH antagonist LHRH agonists hormonerefractory prostate cancer 3 . Patient known hypersensitivity excipients PQR309 . 4 . Patient major surgery within 14 day prior start study drug recover major side effect . 5 . Patients poorly control diabetes mellitus , steroidinduced diabetes mellitus , HbA1c &gt; 7 % , FPG &gt; 7.0 mmol/L ( 125 mg/dL ) . 6 . Patients ( require ) prolong systemic corticosteroid treatment study , except : receiving corticosteroid , patient must stable decrease dose corticosteroid 1 mg dexamethasone day equivalent , i.e . 6 mg prednisone 25 mg hydrocortisone least 5 day prior date enrollment . short duration ( &lt; 5 day ) systemic corticosteroid e.g. , chronic obstructive pulmonary disease , antiemetic correspond maximum antiinflammatory potency 4 mg dexamethasone treatment ; topical application treatment e.g. , rash , inhale spray treatment e.g. , obstructive airway disease , eye drop local Protocol No . PQR309003 Protocol Amendment 3 , 23 September 2015 PIQUR Therapeutics AG Confidential Page 15 108 injection ( e.g. , intraarticular ) ; 7 . Patients take herbal medication certain fruit within 7 day prior start study drug , see section 11.1.2.7 . 8 . Patients concurrent severe and/or uncontrolled medical condition would , investigator 's judgment , contraindicate patient participation clinical study ( e.g. , active uncontrolled severe infection , chronic active hepatitis , immunocompromised , acute chronic pancreatitis , uncontrolled high blood pressure , interstitial lung disease , etc. ) . 9 . Patient known history HIV infection ( test mandatory ) . 10 . Patient follow cardiac abnormality : History , current , document congestive heart failure ( New York Heart Association functional classification III IV ) , document cardiomyopathy . Left Ventricular Ejection Fraction ( LVEF ) &lt; 40 % determined Multiple Gated Acquisition ( MUGA ) scan echocardiogram ( ECHO ) . Myocardial infarction ≤ 6 month prior enrolment . Unstable angina pectoris . Serious uncontrolled cardiac arrhythmia . Symptomatic pericarditis . 11 . Patient impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption study drug . 12 . Concomitant treatment medicinal product increase pH ( reduce acidity ) upper gastrointestinal tract , include , limited , protonpump inhibitor ( e.g . omeprazole ) , H2antagonists ( e.g . ranitidine ) antacid . Patients may enrol study washout period sufficient terminate effect . 13 . Patient history noncompliance medical regimen inability grant consent . 14 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive Human Chorionic Gonadotropin ( hCG ) laboratory test ( &gt; 5 mIU/mL ) . Patients elevate hCG baseline judge related tumor eligible hCG level show expect double repeat 5 7 day later , pregnancy rule vaginal ultrasound . 15 . Patient apply highly effective contraception study screen 90 day discontinue study treatment Protocol No . PQR309003 Protocol Amendment 3 , 23 September 2015 PIQUR Therapeutics AG Confidential Page 16 108 ( see section 11.3 ) . 16 . Patients follow mood disorder judge Investigator Psychiatrist , meet cutoff score ≥ 12 PHQ9 cutoff ≥ 15 GAD7 mood scale , respectively , selects positive response ' 1 , 2 , 3 ' question number 9 regard potential suicidal thought PHQ9 ( independent total score PHQ9 ) see Appendix 4 . Medically documented history active major depressive episode , bipolar disorder ( I II ) , obsessivecompulsive disorder , schizophrenia , history suicidal attempt ideation , homicidal ideation ( immediate risk harm others ) . ≥ CTCAE Grade 3 anxiety . 17 . Patients history interstitial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>oncology , solid tumor</keyword>
</DOC>